Xilio Therapeutics, Inc.

Stage 3 · Topping · week 4

As of Oct 22, 2026, Xilio Therapeutics is in Stage 3, the topping phase, now in week 4 (since Sep 25, 2026). It closed at $8.03, 32.5% below its 52-week high and below its 200-day average, which is falling.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. More about the company

$8.03

-4.75% today

$52.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is XLO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 30w

S1 14w

S4 16w

S1 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 30w → S1 14w → S4 8w → S3 4w → S4 6w → S1 5w → S2 7w → S3 6w → S4 13w → S1 2w → S4 11w → S1 8w → S2 5w → S3 2w → S4 16w → S1 16w → S2 6w → S3 4w current

Total tracked: 165 weeks across 18 stage runs.

XLO among Biotechnology261st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…261	XLOXilio Therapeutics, Inc.	Stage 3 · wk 4	37	−10.2%

vs 52W High

-32.5%

$7.14 lo$11.90 hi

32.5% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 4

1w13w26w

Week 4, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-6.0%

200 DMA: $8.55 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

1.35x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.2%

-7.2%

-5.2%

YTD

-14.6%

-24.0%

Scan Membership

Breakout Watch

Latest: 2024-12-05

3 appearances in last 60 days. First seen: 2023-02-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 4 · Vol 1.35x

2026-10-21S3

Wk 4 · Vol 3.31x

2026-10-20S3

Wk 4 · Vol 1.27x

2026-10-19S3

Wk 4 · Vol 1.08x

2026-10-16S3

Wk 4 · Vol 2.75x

2026-10-15S3

Wk 3 · Vol 0.98x

2026-10-14S3

Wk 3 · Vol 1.15x

2026-10-13S3

Wk 3 · Vol 1.67x

2026-10-12S3

Wk 3 · Vol 0.77x

2026-10-09S3

Wk 3 · Vol 0.51x

2026-10-08S3

Wk 2 · Vol 1.94x

2026-10-07S3

Wk 2 · Vol 0.08x

Moving averages & range

50 DMA

$8.98

200 DMA

$8.55

52W High

$11.90

52W Low

$7.14

5D Low

$8.03

Resistance levels (recent highs)

20d High

$9.22

60d High

$9.50

120d High

$9.58

250d High

$11.90

Next resistance

+14.8%

to 20d High

ROE

-55.0%

Profit margin -34.1%

Dividend Yield

0.00%

P/B 0.7

Xilio Therapeutics: quick answers

What stage is Xilio Therapeutics in?

As of Oct 22, 2026, Xilio Therapeutics (XLO) is in Stage 3, the topping phase. It entered Stage 3 on Sep 25, 2026 and is in week 4. What the four stages mean

Is Xilio Therapeutics in an uptrend?

Its uptrend has stalled. Xilio Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 6.0% below its 200-day average, which is falling.

How far is Xilio Therapeutics from its 52-week high?

Xilio Therapeutics closed at $8.03 on Oct 22, 2026, 32.5% below its 52-week high of $11.90. Its 52-week low is $7.14.

How has Xilio Therapeutics performed over the past year?

As of Oct 22, 2026, Xilio Therapeutics is down 24.0% over the past year and down 14.6% so far in 2026.

Which sector and industry is Xilio Therapeutics in?

Xilio Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.